<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Prothena Corporation Plc — News on 6ix</title>
<link>https://6ix.com/company/prothena-corporation-plc</link>
<description>Latest news and press releases for Prothena Corporation Plc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 27 Apr 2026 20:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/prothena-corporation-plc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835b0e478dffbe2df10fdda.webp</url>
<title>Prothena Corporation Plc</title>
<link>https://6ix.com/company/prothena-corporation-plc</link>
</image>
<item>
<title>Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy</title>
<link>https://6ix.com/company/prothena-corporation-plc/news/prothena-announces-novo-nordisk-obtains-fast-track-designation-from-the-us-fda-for-coramitug-prx004-in-attr-amyloidosis-with-cardiomyopathy</link>
<guid isPermaLink="true">https://6ix.com/company/prothena-corporation-plc/news/prothena-announces-novo-nordisk-obtains-fast-track-designation-from-the-us-fda-for-coramitug-prx004-in-attr-amyloidosis-with-cardiomyopathy</guid>
<pubDate>Mon, 27 Apr 2026 20:05:00 GMT</pubDate>
<description>DUBLIN, April 27, 2026--Prothena announces Novo Nordisk obtains Fast Track Designation from the U.S. FDA for coramitug (PRX004) in ATTR amyloidosis with cardiomyopathy</description>
</item>
<item>
<title>Prothena Announces Leadership Team Updates</title>
<link>https://6ix.com/company/prothena-corporation-plc/news/prothena-announces-leadership-team-updates</link>
<guid isPermaLink="true">https://6ix.com/company/prothena-corporation-plc/news/prothena-announces-leadership-team-updates</guid>
<pubDate>Fri, 10 Apr 2026 04:00:00 GMT</pubDate>
<description>DUBLIN--(BUSINESS WIRE)-- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational</description>
</item>
<item>
<title>Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson’s and Alzheimer’s Disease at AD/PD™ 2026</title>
<link>https://6ix.com/company/prothena-corporation-plc/news/prothena-partners-present-data-supporting-next-generation-treatments-for-parkinsons-and-alzheimers-disease-at-adpdtm-2026</link>
<guid isPermaLink="true">https://6ix.com/company/prothena-corporation-plc/news/prothena-partners-present-data-supporting-next-generation-treatments-for-parkinsons-and-alzheimers-disease-at-adpdtm-2026</guid>
<pubDate>Sat, 21 Mar 2026 04:00:00 GMT</pubDate>
<description>DUBLIN--(BUSINESS WIRE)-- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational</description>
</item>
<item>
<title>Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyopathy</title>
<link>https://6ix.com/company/prothena-corporation-plc/news/prothena-announces-achievement-of-dollar50-million-clinical-milestone-payment-from-novo-nordisk-related-to-ongoing-phase-3-clinical-trial-for-coramitug-formerly-prx004-in-attr-amyloidosis-with-cardiomyopathy-22</link>
<guid isPermaLink="true">https://6ix.com/company/prothena-corporation-plc/news/prothena-announces-achievement-of-dollar50-million-clinical-milestone-payment-from-novo-nordisk-related-to-ongoing-phase-3-clinical-trial-for-coramitug-formerly-prx004-in-attr-amyloidosis-with-cardiomyopathy-22</guid>
<pubDate>Mon, 09 Mar 2026 04:00:00 GMT</pubDate>
<description>Coramitug is a potential first-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy1-3 Prothena has now earned $150</description>
</item>
<item>
<title>Prothena Announces up to $100 Million Share Repurchase Plan</title>
<link>https://6ix.com/company/prothena-corporation-plc/news/prothena-announces-up-to-dollar100-million-share-repurchase-plan</link>
<guid isPermaLink="true">https://6ix.com/company/prothena-corporation-plc/news/prothena-announces-up-to-dollar100-million-share-repurchase-plan</guid>
<pubDate>Fri, 27 Feb 2026 05:00:00 GMT</pubDate>
<description>DUBLIN--(BUSINESS WIRE)-- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational</description>
</item>
<item>
<title>Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights</title>
<link>https://6ix.com/company/prothena-corporation-plc/news/prothena-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-financial-guidance-and-business-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/prothena-corporation-plc/news/prothena-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-financial-guidance-and-business-highlights</guid>
<pubDate>Thu, 19 Feb 2026 21:05:00 GMT</pubDate>
<description>DUBLIN, February 19, 2026--Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights</description>
</item>
<item>
<title>Prothena to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026</title>
<link>https://6ix.com/company/prothena-corporation-plc/news/prothena-report-fourth-quarter-full-210500151</link>
<guid isPermaLink="true">https://6ix.com/company/prothena-corporation-plc/news/prothena-report-fourth-quarter-full-210500151</guid>
<pubDate>Thu, 12 Feb 2026 21:05:00 GMT</pubDate>
<description>DUBLIN, February 12, 2026--Prothena announced that it will report its fourth quarter and full year 2025 financial results on Thursday 2/19/26 with a conference call at 4:30pm ET</description>
</item>
<item>
<title>Prothena Announces Board of Directors Update</title>
<link>https://6ix.com/company/prothena-corporation-plc/news/prothena-announces-board-directors-210500183</link>
<guid isPermaLink="true">https://6ix.com/company/prothena-corporation-plc/news/prothena-announces-board-directors-210500183</guid>
<pubDate>Fri, 12 Dec 2025 21:05:00 GMT</pubDate>
<description>DUBLIN, December 12, 2025--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that Paula Cobb will step down from Prothena’s Board of Directors to join Manifold Bio as its Chief Operating Officer. During her six-year tenure, Ms. Cobb played a significant role in which she made key contributions to the Company’s vision and strategy.</description>
</item>
<item>
<title>Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025</title>
<link>https://6ix.com/company/prothena-corporation-plc/news/prothena-announces-poster-presentation-tdp-210500315</link>
<guid isPermaLink="true">https://6ix.com/company/prothena-corporation-plc/news/prothena-announces-poster-presentation-tdp-210500315</guid>
<pubDate>Wed, 19 Nov 2025 21:05:00 GMT</pubDate>
<description>DUBLIN, Ireland, November 19, 2025--Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025</description>
</item>
<item>
<title>Prothena Highlights Phase 2 Data for Coramitug (Formerly PRX004) Published in Circulation, Official Journal of AHA</title>
<link>https://6ix.com/company/prothena-corporation-plc/news/prothena-highlights-phase-2-data-140000851</link>
<guid isPermaLink="true">https://6ix.com/company/prothena-corporation-plc/news/prothena-highlights-phase-2-data-140000851</guid>
<pubDate>Tue, 11 Nov 2025 14:00:00 GMT</pubDate>
<description>DUBLIN, November 11, 2025--Phase 2 clinical data for coramitug, a potential first-in-class amyloid depleter antibody, for the treatment of ATTR-CM published in Circulation.</description>
</item>
<item>
<title>Prothena Reports Third Quarter 2025 Financial Results and Business Highlights</title>
<link>https://6ix.com/company/prothena-corporation-plc/news/prothena-reports-third-quarter-2025-210500008</link>
<guid isPermaLink="true">https://6ix.com/company/prothena-corporation-plc/news/prothena-reports-third-quarter-2025-210500008</guid>
<pubDate>Thu, 06 Nov 2025 21:05:00 GMT</pubDate>
<description>DUBLIN, November 06, 2025--Prothena today reported financial results for the third quarter and first nine months of 2025 and provided business highlights.</description>
</item>
<item>
<title>Prothena to Report Third Quarter 2025 Financial Results on November 6</title>
<link>https://6ix.com/company/prothena-corporation-plc/news/prothena-report-third-quarter-2025-200500085</link>
<guid isPermaLink="true">https://6ix.com/company/prothena-corporation-plc/news/prothena-report-third-quarter-2025-200500085</guid>
<pubDate>Thu, 30 Oct 2025 20:05:00 GMT</pubDate>
<description>DUBLIN, Ireland, October 30, 2025--Prothena will report its third quarter 2025 financial results on Thursday November 6, 2025, after the close of the U.S. financial markets.</description>
</item>
<item>
<title>Prothena’s Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer’s Disease</title>
<link>https://6ix.com/company/prothena-corporation-plc/news/prothena-partner-bristol-myers-squibb-204500268</link>
<guid isPermaLink="true">https://6ix.com/company/prothena-corporation-plc/news/prothena-partner-bristol-myers-squibb-204500268</guid>
<pubDate>Wed, 01 Oct 2025 20:45:00 GMT</pubDate>
<description>DUBLIN, October 01, 2025--PRTA announced that BMS communicated that the FDA granted Fast Track Designation to BMS-986446, an anti-tau antibody in P2 for Alzheimer's disease.</description>
</item>
<item>
<title>Prothena to Participate in the Cantor Fitzgerald Global Healthcare Conference</title>
<link>https://6ix.com/company/prothena-corporation-plc/news/prothena-participate-cantor-fitzgerald-global-200500150</link>
<guid isPermaLink="true">https://6ix.com/company/prothena-corporation-plc/news/prothena-participate-cantor-fitzgerald-global-200500150</guid>
<pubDate>Thu, 28 Aug 2025 20:05:00 GMT</pubDate>
<description>DUBLIN, August 28, 2025--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior management team will participate in a fireside chat at the Cantor Fitzgerald Global Healthcare Conference on Thursday, September 4, 2025 at 10:55 a.m. ET in New York, NY.</description>
</item>
<item>
<title>Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program</title>
<link>https://6ix.com/company/prothena-corporation-plc/news/prothena-provides-prx012-announces-results-200500822</link>
<guid isPermaLink="true">https://6ix.com/company/prothena-corporation-plc/news/prothena-provides-prx012-announces-results-200500822</guid>
<pubDate>Wed, 27 Aug 2025 20:05:00 GMT</pubDate>
<description>DUBLIN, August 27, 2025--Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program</description>
</item>
<item>
<title>Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy</title>
<link>https://6ix.com/company/prothena-corporation-plc/news/prothena-announces-novo-nordisk-advance-130000158</link>
<guid isPermaLink="true">https://6ix.com/company/prothena-corporation-plc/news/prothena-announces-novo-nordisk-advance-130000158</guid>
<pubDate>Wed, 06 Aug 2025 13:00:00 GMT</pubDate>
<description>DUBLIN, August 06, 2025--Prothena announced that Novo Nordisk communicated that they expect to advance coramitug into a Phase 3 program for ATTR-CM in 2025.</description>
</item>
<item>
<title>Prothena Reports Second Quarter 2025 Financial Results and Business Highlights</title>
<link>https://6ix.com/company/prothena-corporation-plc/news/prothena-reports-second-quarter-2025-200500383</link>
<guid isPermaLink="true">https://6ix.com/company/prothena-corporation-plc/news/prothena-reports-second-quarter-2025-200500383</guid>
<pubDate>Mon, 04 Aug 2025 20:05:00 GMT</pubDate>
<description>DUBLIN, August 04, 2025--Prothena today reported financial results for the second quarter and first six months of 2025 and provided business highlights.</description>
</item>
<item>
<title>Prothena to Report Second Quarter 2025 Financial Results on August 4</title>
<link>https://6ix.com/company/prothena-corporation-plc/news/prothena-report-second-quarter-2025-200500656</link>
<guid isPermaLink="true">https://6ix.com/company/prothena-corporation-plc/news/prothena-report-second-quarter-2025-200500656</guid>
<pubDate>Mon, 28 Jul 2025 20:05:00 GMT</pubDate>
<description>DUBLIN, July 28, 2025--Prothena today announced that it will report its second quarter and first six months of 2025 financial results on August 4, 2025.</description>
</item>
<item>
<title>Prothena Announces Corporate Restructuring</title>
<link>https://6ix.com/company/prothena-corporation-plc/news/prothena-announces-corporate-restructuring-200500761</link>
<guid isPermaLink="true">https://6ix.com/company/prothena-corporation-plc/news/prothena-announces-corporate-restructuring-200500761</guid>
<pubDate>Wed, 18 Jun 2025 20:05:00 GMT</pubDate>
<description>DUBLIN, June 18, 2025--Prothena announced that the Company has initiated an approximate 63% reduction in its workforce.</description>
</item>
<item>
<title>Prothena’s Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease</title>
<link>https://6ix.com/company/prothena-corporation-plc/news/prothena-partner-roche-advance-prasinezumab-050600533</link>
<guid isPermaLink="true">https://6ix.com/company/prothena-corporation-plc/news/prothena-partner-roche-advance-prasinezumab-050600533</guid>
<pubDate>Mon, 16 Jun 2025 05:06:00 GMT</pubDate>
<description>DUBLIN, June 16, 2025--Prothena announced partner Roche will advance prasinezumab into Phase III development in early-stage Parkinson’s disease.</description>
</item>
</channel>
</rss>